Immune checkpoint blockade (ICB) therapy, primarily anti-PD-1/PD-L1 and anti-CTLA-4, has been shown to induce remarkable response across different cancers in multiple clinical cohorts [1–8]. This evidence concerns the gene CTLA4 and cancer.